Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Conditions:   Advanced EGFR-mutant Non-smallcell Lung Cancer;   Head-and-Neck Squamous Cell Cancer;   RAS/RAF Wild-type Other Solid Tumors
Intervention:   Drug: TNO155
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified April 2017

http://ift.tt/2oZ7WDS